This article is more than 5 years old. Information may no longer be current.
Pain relief injections poor predictors of outcomes after hip arthroscopy
Click Here to Manage Email Alerts
LAS VEGAS — Pain relief from intra-articular injection poorly predicted short-term outcomes after patients underwent hip arthroscopy for femoracetabular impingement, according to data presented at the American Academy of Orthopaedic Surgeons Annual Meeting.
Researchers reviewed the medical records of 96 patients (mean age: 37.5 years) who underwent hip arthroscopy for femoracetabular impingement between April 2007 and April 2012, identifying those who underwent intra-articular (IA) injection and subsequent hip arthroscopy. The researchers reviewed preoperative radiographs and, utilizing the Tonnis classification system, they determined patients’ degree of osteoarthritis. Additionally, the Modified Harris Hip Score (MHHS) and Hip Outcome Score (HOS) were used to assess whether outcomes were associated with percent of pain relief.
Results showed 26 patients had a Tonnis grade of 0, 55 had a Tonnis grade of 1 and 18 had a Tonnis grade of 2. Overall, mean pain relief following IA injection was 73.6, according to the researchers. Of the patients studied, 26 (26%) obtained less than 50% of pain relief after the IA injection and 73 patients (74%) obtained greater than 50% of pain relief. The MHHS and HOS mean scores were 79.2 and 67.4, respectively.
Although patients who received IA injection and experienced more than 50% pain relief were more likely to experience positive results, the likelihood ratio of 1.15 was not considered statistically significant, according to the researchers.
Age, gender, Tonnis grade, percent relief after the IA injection, number of months postoperatively and surgery type were also found to not significantly predict short-term outcomes, according to the researchers. ‒ by Monica Jaramillo
Reference:
Krych AJ, et al. Paper #427. Presented at: American Academy of Orthopaedic Annual Meeting; March 24-28, 2015; Las Vegas.
Disclosures: Krych reports he is a paid consultant for Arthrex and receives research support from the Arthritis foundation and Histogenics. Please see the full abstract for a list of all other authors’ relevant financial disclosures.